Navigation Links
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Date:5/16/2013

es, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies.

 

This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets.

 

Competitor projects are listed in a tabular format providing Information on:

 

• Drug Codes,

• Target / Mechanism of Action,

• Class of Compound,

• Company,

• Product Category,

• Indication,

• R&D Stage and

• additional comments with a hyperlink leading to the source of information.

 

About Competitor Analysis Series:

 

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

 

 

Table of Contents

 

1) Erythropoiesis Stimulating Agents (ESA)

 

• First generation epoetins in regulated markets

• Second generation epoetins in regulated markets

• Epoetin biosimilars in regulated markets

• Darbepoetin biosimilars in regulated markets

• Next generation biologic Eythropoiesis Stimulating Agents (ESA) in
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
6. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
9. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014   GenoSpace , a precision medicine ... tools to enable the broad use of genomic data ... has been awarded Phase I of a Fast Track ... Institutes of Health (NIH) to enable enhanced data access ... http://photos.prnewswire.com/prnh/20140922/147649 During the past ...
(Date:9/23/2014)... 2014 Marktech Optoelectronics has introduced the ... emitters in the 280 nm wavelength range. This series ... range from 280nm to 405nm. These new devices are ... well as curing. Mark Campito, Marktech’s CEO states that ... to manufacturers is that we offer it in one ...
(Date:9/23/2014)... The Minnesota High Tech Association (MHTA) ... modems , platforms and application-specific remote monitoring systems, ... the 2014 Tekne Awards. The awards ceremony ... Center on Thursday, November 13th. The Tekne Awards ... superior technology innovation and leadership. , The ...
(Date:9/22/2014)... Pearl's Premium Ultra Low Maintenance Lawn Seed announced ... this week with the release of their Pearl's Premium, ... fact that it is time to plant now and ... As of the date 6/4/13, Pearl's Premium had well ... and the media including: The National Gardeners Assoc. ...
Breaking Biology Technology:GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2Marktech Introduces its New Line of Deep UV Emitters 2NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2
... Boston Scientific,Corporation (NYSE: BSX ) today announced financial ... as guidance for net sales and,earnings per share (EPS) for ... -- Reported net sales of $1.978 billion and adjusted ... market leadership -- Achieved worldwide cardiac rhythm management (CRM) ...
... Holding Company to Strengthen ... Acquires Research and Product Development Company to Expedite Product ... ... at 8:00 am E.T., NEW YORK, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, ...
... $165 Million Line of Credit to ... Amylin, ... ) and Eli Lilly and Company (NYSE: LLY ),today announced they have ... if approved, would,become the first once weekly therapy to treat type 2 diabetes. ...
Cached Biology Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27American Oriental Bioengineering Completes Two Acquisitions 2American Oriental Bioengineering Completes Two Acquisitions 3American Oriental Bioengineering Completes Two Acquisitions 4Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 2Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 3
(Date:9/21/2014)... protein therapy that disrupts the process that causes cancer ... through the blood stream and start aggressive new growths ... metastasis, can cause cancer to spread with deadly effect. ... cancer fall prey to metastatic forms of the disease," ... describes a new therapeutic approach in Nature Chemical ...
(Date:9/19/2014)... the unique bioelectric signaling system of the electric fish, ... The OU researcher is working to understand how these ... used to map the world around them. Electric ... discharges a second throughout their lives. The energetic ... necessary for survival. , "There is evidence that electric ...
(Date:9/19/2014)... which over thousands of years has adapted to the arctic ... makes the cold dangerous for you. , This is happening ... the cold provoking substance, called nonylphenol, comes from the use ... of being a endocrine disruptor, but when entering the worm ... to protect the cells in its body from cold damage. ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... have just provided the medical community a new way of ... of life forms and functions. University of Central Florida ... to analyze RNA motifs the subunits that make up ... building blocks of life along with DNA and proteins. ...
... stem cell study conducted in mice suggests a novel ... a heart attack. The approach potentially could improve cardiac ... new blood vessels and avoid the risk of ... the journal PLoS ONE , ( http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0030329 ) ...
... Biology Organization (EMBO) and the Federation of European ... the Friedrich Miescher Institute for Biomedical Research in ... FEBS/EMBO Women in Science Award. Professor Gasser has ... genome stability and epigenetics and her commitment to ...
Cached Biology News:Stem cell study in mice offers hope for treating heart attack patients 2Stem cell study in mice offers hope for treating heart attack patients 3Susan M. Gasser to receive the 2012 FEBS/EMBO Women in Science Award 2
Normal canine serum collected from healthy normal canines....
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
RABBIT ANTI GLYCINE...
... Light Diagnostics Cytomegalovirus (CMV) pp65 Antigenemia Immunofluorescence ... identification of lower matrix protein pp65 of ... Kit Components: Erythrocyte ... bottle containing 220 mL of buffered ammonium ...
Biology Products: